AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19307034 — intervention group
Group type: COMPARATOR
Intervention: Multiple-fraction radiotherapy (3 Gy x 10)
Number of subjects: 180
Study 16685010 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol, 9 microg
Number of subjects: 24
Study 16685010 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline, 0.5 mg
Number of subjects: 24
Study 16685010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15281978 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene (Gore‐Tex) suture
Number of subjects: 30
Study 15281978 — intervention group
Group type: COMPARATOR
Intervention: Braided polyester (Ethibond) suture
Number of subjects: 30
Study 11693252 — intervention group
Group type: EXPERIMENTAL
Intervention: Old skills executed in the context of a new task
Number of subjects: 0
Study 11693252 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in task complexity from training to transfer
Number of subjects: 0
Study 11693252 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative change in task complexity
Number of subjects: 0
Study 11693252 — intervention group
Group type: EXPERIMENTAL
Intervention: Response times in transfer tasks
Number of subjects: 0
Study 11693252 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance accuracy
Number of subjects: 0
Study 9130381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive family preservation services (experimental group)
Number of subjects: 134
Study 9130381 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intensive family preservation services)
Number of subjects: 134
Study 8189174 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography only
Number of subjects: 3726
Study 8189174 — intervention group
Group type: COMPARATOR
Intervention: Mammography plus EPIC study
Number of subjects: 3726
Study 3332610 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine at doses up to 20 mg/day
Number of subjects: 15
Study 3332610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29219954 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantation of STARFlex devices for PFO closure
Number of subjects: 0
Study 29219954 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 0
Study 27287699 — intervention group
Group type: COMPARATOR
Intervention: Alirocumab 150 mg every 4 weeks plus placebo
Number of subjects: 24
Study 27287699 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg every 4 weeks plus ezetimibe
Number of subjects: 24
Study 27287699 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg every 4 weeks plus fenofibrate
Number of subjects: 24
Study 24509204 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation ON
Number of subjects: 21
Study 24509204 — intervention group
Group type: COMPARATOR
Intervention: Sacral nerve stimulation OFF
Number of subjects: 21
Study 24509204 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation
Number of subjects: 21
Study 22440981 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 55
Study 22440981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 20308876 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin adhesive
Number of subjects: 175
Study 20308876 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 175
Study 18382839 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based program intervention
Number of subjects: 76
Study 18382839 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (control)
Number of subjects: 76
Study 18382839 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention classrooms
Number of subjects: 76
Study 16022756 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented soya milk (40 mg isoflavone)
Number of subjects: 16
Study 16022756 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented soya milk
Number of subjects: 16
Study 16022756 — intervention group
Group type: COMPARATOR
Intervention: Non-fermented soya milk
Number of subjects: 16
Study 16022756 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 16022756 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing isoflavone dosage
Number of subjects: 16
Study 16022756 — intervention group
Group type: EXPERIMENTAL
Intervention: Modest dosage (20-30 mg/d)
Number of subjects: 16
Study 14727988 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate 200 mg/day (capsules)
Number of subjects: 7098
Study 14727988 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate 160 mg once daily (tablet)
Number of subjects: 7098
Study 14727988 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (tablet and capsule formulations)
Number of subjects: 7098
Study 14727988 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate
Number of subjects: 7098
Study 10407838 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic thought disorder (productive)
Number of subjects: 0
Study 10407838 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic thought disorder (negative)
Number of subjects: 0
Study 10407838 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline thought disorder
Number of subjects: 0
Study 7781149 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral trofosfamide, escalated doses every 3rd week until grade 2 leukopenia
Number of subjects: 23
Study 2281055 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride inhalation (0.3 mg/ml)
Number of subjects: 10
Study 2281055 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline inhalation
Number of subjects: 10
Study 443080 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microgram of 1,25-dihydroxycholecalciferol per day for 10 days
Number of subjects: 12
Study 443080 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microgram of 25-hydroxycholecalciferol per day for 10 days
Number of subjects: 12
Study 31503309 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent home-based physical therapy intervention (training)
Number of subjects: 210
Study 31503309 — intervention group
Group type: COMPARATOR
Intervention: Active control (transcutaneous electrical nerve stimulation and active range-of-motion exercises)
Number of subjects: 210
Study 28911357 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination intervention package to improve early initiation of ART and anti-tuberculosis treatment success
Number of subjects: 1233
Study 27106971 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath™
Number of subjects: 720
Study 27106971 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐MAC™ D‐blade
Number of subjects: 720
Study 27106971 — intervention group
Group type: EXPERIMENTAL
Intervention: KingVision™
Number of subjects: 720
Study 27106971 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope™
Number of subjects: 720
Study 27106971 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq™
Number of subjects: 720
Study 27106971 — intervention group
Group type: EXPERIMENTAL
Intervention: A.P. Advance™ difficult airway blade
Number of subjects: 720
Study 27106971 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall success, laryngeal view, and intubation times
Number of subjects: 720
Study 27106971 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-effects
Number of subjects: 720
Study 24848522 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure (AA)
Number of subjects: 305
Study 24848522 — intervention group
Group type: COMPARATOR
Intervention: Sham auricular acupressure (Sham-AA)
Number of subjects: 305
Study 24848522 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 305
Study 22352745 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 99
Study 22352745 — intervention group
Group type: COMPARATOR
Intervention: LMA Classic
Number of subjects: 99
Study 21336014 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator circuits changed every 14 days (experimental group)
Number of subjects: 79
Study 21336014 — intervention group
Group type: COMPARATOR
Intervention: Ventilator circuits changed every 7 days (control group)
Number of subjects: 79
Study 17940861 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated individual cognitive-behavioral treatment and HIV prevention intervention
Number of subjects: 180
Study 17940861 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 180
Study 17940861 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment conditions
Number of subjects: 180
Study 16219571 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT)
Number of subjects: 222
Study 16219571 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous SCT
Number of subjects: 222
Study 16219571 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 222
Study 16219571 — intervention group
Group type: COMPARATOR
Intervention: Delayed intensification followed by maintenance chemotherapy
Number of subjects: 222
Study 12058100 — intervention group
Group type: EXPERIMENTAL
Intervention: Talampanel
Number of subjects: 49
Study 12058100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 10604701 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser ablation of the prostate (KTP/neodymium: yttrium‐aluminum‐garnet laser)
Number of subjects: 100
Study 10604701 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 100
Study 7547040 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal amethocaine 12 mg in 2 ml of 5% glucose
Number of subjects: 40
Study 7547040 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal amethocaine 14 mg in 2 ml of 5% glucose
Number of subjects: 40
Study 7547040 — intervention group
Group type: COMPARATOR
Intervention: Spinal amethocaine 8 mg in 2 ml of 5% glucose
Number of subjects: 40
Study 1540304 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic acid (15 mg bid, po)
Number of subjects: 5
Study 1540304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 3886712 — intervention group
Group type: EXPERIMENTAL
Intervention: Arildone in vanishing cream
Number of subjects: 0
Study 3886712 — intervention group
Group type: EXPERIMENTAL
Intervention: Arildone in DMSO solution
Number of subjects: 0
Study 3886712 — intervention group
Group type: COMPARATOR
Intervention: Vanishing cream vehicle without arildone
Number of subjects: 0
Study 3886712 — intervention group
Group type: COMPARATOR
Intervention: DMSO solution vehicle without arildone
Number of subjects: 0
Study 30381001 — intervention group
Group type: EXPERIMENTAL
Intervention: POL training (polarized)
Number of subjects: 20
Study 30381001 — intervention group
Group type: COMPARATOR
Intervention: THR training (threshold)
Number of subjects: 20
Study 30053897 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen therapy (HFNO2)
Number of subjects: 0
Study 30053897 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy (standard low flow oxygen therapy)
Number of subjects: 0
Study 27026675 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (high dose: 8 mg/kg)
Number of subjects: 18111
Study 27026675 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (low dose: 4 mg/kg)
Number of subjects: 18111
Study 27026675 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab for 1 year
Number of subjects: 18111
Study 27026675 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab for 2 years
Number of subjects: 18111
Study 27026675 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab for 9 weeks
Number of subjects: 18111
Study 27026675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18111
Study 25350900 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert modeling
Number of subjects: 20
Study 25350900 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice-over PowerPoint
Number of subjects: 20
Study 25350900 — intervention group
Group type: COMPARATOR
Intervention: Reading assignments
Number of subjects: 20
Study 25185361 — intervention group
Group type: EXPERIMENTAL
Intervention: Bufei granule
Number of subjects: 140
Study 25185361 — intervention group
Group type: COMPARATOR
Intervention: Bufei placebo
Number of subjects: 140
Study 21116604 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD‐alum (20 μg subcutaneous injection at baseline and 1 month later)
Number of subjects: 70
Study 21116604 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous injection at baseline and 1 month later)
Number of subjects: 70
Study 21116604 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD‐alum
Number of subjects: 70
Study 21116604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 19181715 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) group
Number of subjects: 110
Study 19181715 — intervention group
Group type: COMPARATOR
Intervention: Successful Aging (SA) control group
Number of subjects: 110
Study 17426112 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil Red O (ORO) staining
Number of subjects: 18
Study 17426112 — intervention group
Group type: EXPERIMENTAL
Intervention: (1)H‐MR spectroscopy (MRS)
Number of subjects: 18
Study 17426112 — intervention group
Group type: COMPARATOR
Intervention: Biochemical assay (BIO)
Number of subjects: 18
Study 15223098 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention (1-hour session)
Number of subjects: 200
Study 12536654 — intervention group
Group type: EXPERIMENTAL
Intervention: Livial
Number of subjects: 56
Study 12536654 — intervention group
Group type: COMPARATOR
Intervention: Oryzanol and Vitamin E
Number of subjects: 56
Study 9695723 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine 21 mg/24 hr
Number of subjects: 12
Study 9695723 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine 42 mg/24 hr
Number of subjects: 12
Study 9695723 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine 63 mg/24 hr
Number of subjects: 12
Study 9695723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9695723 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (all doses)
Number of subjects: 12
Study 9695723 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine with smoking
Number of subjects: 12
Study 7626984 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (erythropoietin + calcitriol)
Number of subjects: 17
Study 7626984 — intervention group
Group type: COMPARATOR
Intervention: Erythropoietin monotherapy
Number of subjects: 17
Study 1720403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iloprost
Number of subjects: 151
Study 1720403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 7053590 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser conization
Number of subjects: 110
Study 7053590 — intervention group
Group type: COMPARATOR
Intervention: Cold knife conization
Number of subjects: 110
Study 31996953 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta/interleukin-2 immunotherapy added to first-line salvage hormone therapy (HT)
Number of subjects: 26
Study 31996953 — intervention group
Group type: COMPARATOR
Intervention: Historical controls receiving first-line salvage hormone therapy (HT)
Number of subjects: 26
Study 30296337 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE intervention (psychotherapy delivered via telephone, 5 sessions over 7 weeks)
Number of subjects: 59
Study 30296337 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE intervention
Number of subjects: 59
Study 30296337 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Social Work Control arm
Number of subjects: 59
Study 28964890 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐981 (0.3, 1, or 3 mg/kg) every other week for a total of four SC injections
Number of subjects: 36
Study 28964890 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐981 (3 mg/kg) every 4 weeks for a total of three SC injections
Number of subjects: 36
Study 28964890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 24491349 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated SMS reminders
Number of subjects: 62
Study 24491349 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 62
Study 23145795 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 134
Study 23145795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 22674612 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/day)
Number of subjects: 135
Study 22674612 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed (500 mg/m2 on day 1, every 3 weeks)
Number of subjects: 135
Study 22674612 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 135
Study 22674612 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed
Number of subjects: 135
Study 22674612 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (in patients with EGFR mutation)
Number of subjects: 135
Study 22674612 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed (in patients with EGFR mutation)
Number of subjects: 135
Study 22674612 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (in patients without EGFR mutation)
Number of subjects: 135
Study 22674612 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed (in patients without EGFR mutation)
Number of subjects: 135
Study 22674612 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib and Pemetrexed
Number of subjects: 135
Study 19023279 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/day)
Number of subjects: 55
Study 19023279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 17562951 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 414
Study 17562951 — intervention group
Group type: COMPARATOR
Intervention: Iodixanol
Number of subjects: 414
Study 17562951 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol (diabetes patients)
Number of subjects: 414
Study 17562951 — intervention group
Group type: COMPARATOR
Intervention: Iodixanol (diabetes patients)
Number of subjects: 414
Study 15064218 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-administered intervention
Number of subjects: 113
Study 15064218 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced counseling (physician + counselor)
Number of subjects: 113
Study 15064218 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention
Number of subjects: 113
Study 11447379 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (30 mg twice daily for 3 days)
Number of subjects: 10
Study 10410574 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic renal allograft rejection (Group I)
Number of subjects: 34
Study 10410574 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable allograft function (Group II)
Number of subjects: 34
Study 10410574 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control)
Number of subjects: 34
Study 10410574 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic renal allograft rejection (Group I) and stable graft function (Group II)
Number of subjects: 34
Study 8064166 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (1 mg/kg, oral)
Number of subjects: 53
Study 8064166 — intervention group
Group type: EXPERIMENTAL
Intervention: Remikiren (1 mg/kg, intravenous infusion over 60 min)
Number of subjects: 53
Study 8064166 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug)
Number of subjects: 53
Study 1932670 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose terlipressin
Number of subjects: 40
Study 1932670 — intervention group
Group type: COMPARATOR
Intervention: Low-dose terlipressin
Number of subjects: 40
Study 6119724 — intervention group
Group type: EXPERIMENTAL
Intervention: Melperone 10 mg
Number of subjects: 8
Study 6119724 — intervention group
Group type: EXPERIMENTAL
Intervention: Melperone 25 mg
Number of subjects: 8
Study 6119724 — intervention group
Group type: EXPERIMENTAL
Intervention: Melperone 50 mg
Number of subjects: 8
Study 6119724 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine 10 mg
Number of subjects: 8
Study 6119724 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine 25 mg
Number of subjects: 8
Study 6119724 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine 50 mg
Number of subjects: 8
Study 6119724 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomepromazine 10 mg
Number of subjects: 8
Study 6119724 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomepromazine 25 mg
Number of subjects: 8
Study 6119724 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomepromazine 50 mg
Number of subjects: 8
Study 6119724 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorprotixene 10 mg
Number of subjects: 8
Study 6119724 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorprotixene 25 mg
Number of subjects: 8
Study 6119724 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorprotixene 50 mg
Number of subjects: 8
Study 6119724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30719615 — intervention group
Group type: EXPERIMENTAL
Intervention: Olweus Bully Prevention Program (OBPP) combined with a family intervention
Number of subjects: 2859
Study 29193937 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 170
Study 29193937 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 170
Study 29193937 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Tamsulosin and Oxybutynin
Number of subjects: 170
Study 29193937 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment mentioned)
Number of subjects: 170
Study 25549690 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based phoneme-discrimination training (twice a week for three weeks)
Number of subjects: 27
Study 25549690 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 27
Study 24060767 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 30